KALY Kali Inc.

KALY - Kali-Extracts Expects 2020 Revenue Growth Acceleration from CBD Infused Consumer Products

Dallas, Texas--(Newsfile Corp. - December 11, 2019) - Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (OTC Pink: KALY) ("KALY") today announced expected revenue growth acceleration in 2020 from the sales of CBD infused consumer products. The company currently generates revenue from the sale of CBD infused candies and beverages. KALY produces and sells Hemp4mula chewing gum and gummies available on and it has licensed its patented cannabis extraction process for the production of CBD infused beverages. KALY has recently announced a restructuring of its cannabis biopharmaceutical business as part of a strategy to facilitate a strategic investment at a $50 million valuation. The restructuring is also anticipated to facilitate increased investment and operational focus benefiting KALY's consumer products business from which management expects to see accelerated revenue growth in 2020. KALY management believes the company may realize its first $1 million in annual sales by year end 2019, and that the current restructuring can accelerate sales form CBD infused consumer products next year. Accelerated growth is anticipated from a distribution network expansion and the introduction of new CBD infused consumer products.

To stay abreast of the latest developments and learn more about the company visit .

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.

CONTACT:
Frederick Ferri

(214) 210-0459

To view the source version of this press release, please visit

EN
11/12/2019

Underlying

KALYKali Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kali Inc.

 PRESS RELEASE
Free
KALY KALI INC.

CORRECTION FROM SOURCE: KALY Exits Cannabis Business With Shareholder ...

This document corrects and replaces the press release that was issued by Kali Inc. (OTC Pink: KALY) (“KALY”) today July 16, 2020 at 11:24 am ET. The release below replaces the entirety of the previous release, as the incorrect release was sent.The corrected press release follows in full below:Dallas, Texas--(Newsfile Corp. - July 16, 2020) - Kali, Inc. (OTC Pink: KALY) ("KALY") today announced a deal in the works to sell its cannabis execration subsidiary, NCM Biotech, to PAO Group, Inc. (OTC Pink: PAOG) in exchange for common shares of PAOG that will in turn be issued to KALY shareholders in ...

July 16, 2020 1 EN
 PRESS RELEASE
Free
KALY KALI INC.

KALY Calls for Partners on Patented Technology and Potential COVID-19 ...

Dallas, Texas--(Newsfile Corp. - July 16, 2020) - Kali-Extracts, Inc. (OTC Pink: KALY) (Kali, Inc. dba/Kali-Extracts, Inc.) ("KALY") today issued a call for potential partners that could contribute to the acceleration of evaluating and developing KALY's proprietary CBD formulation developed for the treatment of symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions. Researchers believe the CBD formulation could be effective in the treatment of symptoms resulting from COVID-19.The formulation for the treatment of symptoms associated with C...

July 16, 2020 1 EN
 PRESS RELEASE
Free
KALY KALI INC.

KALY Previews Investment Commitment Into Its Cannabis Biopharmaceutica...

Dallas, Texas--(Newsfile Corp. - February 3, 2020) - Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (OTC Pink: KALY) ("KALY"), today previewed a Letter of Intent (LOI) executed with a third-party investor. The LOI details are anticipated to be released tomorrow. Management indicates the two-stage investment is of substantial magnitude and can meaningfully advance the company's ongoing development of its cannabis biopharmaceutical technology. KALY has a U.S. Patented Cannabis Extraction Process it uses to produce proprietary formulations for the treatment of various medical conditi...

February 3, 2020 1 EN
 PRESS RELEASE
Free
KALY KALI INC.

KALY Patented Cannabis Biotech $50 Million Valuation Supported By Anal...

Dallas, Texas--(Newsfile Corp. - January 31, 2020) - Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (OTC Pink: KALY) ("KALY") today pointed to a on the legal marijuana market projecting the legal marijuana market to reach over $66 Billion in value by 2025 to support a recent $50 Million valuation of KALY's cannabis biotechnology. KALY has U.S. Patented Cannabis Extraction Process it uses to produce proprietary formulations for the treatment of various medical conditions. Grand View Research indicates the growing adoption of cannabis as a pharmaceutical is a substantial driver be...

January 31, 2020 1 EN
 PRESS RELEASE
Free
KALY KALI INC.

KALY- Kali-Extracts Proprietary CBD Extract Could Offer Coronavirus Re...

Dallas, Texas--(Newsfile Corp. - January 29, 2020) - Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (OTC Pink: KALY) ("KALY") today confirmed efforts to evaluate its proprietary CBD extract formulation as a treatment for coronavirus symptoms. KALY's proprietary CBD formulation has been developed for the treatment of symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions. The formulation for the treatment of symptoms associated with COPD and other similar respiratory conditions has been derived from the company's U.S. Patented...

January 29, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch